Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL231 Solution for Inhalation in COPD – Phase II Crossover PK/PD Study
CTR20212985Phase 2Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HL231 Solution for Inhalation in chronic obstructive pulmonary disease (COPD), sponsored by Sichuan Haisco Pharmaceutical Co., Ltd.. Started Nov 2021; status: completed.
02
Drugs
HL231 Solution for Inhalation
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20212985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212985.